{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:10:44Z","timestamp":1775466644634,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.thromres.2010.11.030","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T09:05:26Z","timestamp":1294650326000},"page":"247-253","source":"Crossref","is-referenced-by-count":14,"title":["Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate\u00ae, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients"],"prefix":"10.1016","volume":"127","author":[{"given":"Anna","family":"Klukowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Batorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2010.11.030_bb0005","first-page":"104","article-title":"The hemophilias: progress and problems","volume":"36","author":"Mannucci","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.thromres.2010.11.030_bb0010","series-title":"Clinical manifestations and therapy of inherited coagulation factor deficiencies","first-page":"169","author":"Brettler","year":"1994"},{"key":"10.1016\/j.thromres.2010.11.030_bb0015","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/S0021-9258(18)47430-3","article-title":"A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor","volume":"262","author":"Foster","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2010.11.030_bb0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1432-1033.1987.tb13480.x","article-title":"Factor VIII binds to von Willebrand factor via its Mr-80, 000 light chain","volume":"166","author":"Hamer","year":"1987","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.thromres.2010.11.030_bb0025","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1172\/JCI113721","article-title":"Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor","volume":"82","author":"Koedam","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2010.11.030_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1432-1033.1990.tb15481.x","article-title":"The effect of von Willebrand factor on activation of factor VIII by factor Xa","volume":"189","author":"Koedam","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.thromres.2010.11.030_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/bi00350a035","article-title":"Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity","volume":"25","author":"Eaton","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2010.11.030_bb0040","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.str.2008.03.001","article-title":"Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex","volume":"16","author":"Ngo","year":"2008","journal-title":"Structure"},{"key":"10.1016\/j.thromres.2010.11.030_bb0045","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2007-08-109918","article-title":"The tertiary structure and domain organization of coagulation factor VIII","volume":"111","author":"Shen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.11.030_bb0050","author":"Farrugia"},{"key":"10.1016\/j.thromres.2010.11.030_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00217358","article-title":"Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation","volume":"91","author":"Wise","year":"1993","journal-title":"Hum Genet"},{"key":"10.1016\/j.thromres.2010.11.030_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.biologicals.2005.11.010","article-title":"Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate)","volume":"34","author":"Stadler","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.thromres.2010.11.030_bb0070","author":"US Food and Drug Administration"},{"key":"10.1016\/j.thromres.2010.11.030_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease\u2013efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2010.11.030_bb0080","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0038-1646423","article-title":"The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII\/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis","volume":"66","author":"Morfini","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.11.030_bb0085","series-title":"Factor VIII - von Willebrand Factor","first-page":"33","article-title":"Clinical and laboratory assessment of patients with haemophilia","author":"Beard","year":"1989"},{"key":"10.1016\/j.thromres.2010.11.030_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0609.2008.01049.x","article-title":"A systematic overview of the first pasteurised VWF\/FVIII medicinal product, Haemate P\/ Humate -P: history and clinical performance","author":"Berntorp","year":"2008","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.thromres.2010.11.030_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1432-1033.1987.tb13331.x","article-title":"The effect of thrombin on the complex between factor VIII and von Willebrand factor","volume":"167","author":"Hamer","year":"1987","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.thromres.2010.11.030_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01703248","article-title":"Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology","volume":"63","author":"Kaufman","year":"1991","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2010.11.030_bb0105","article-title":"Product features of novel generation VWF\/FVIII concentrate in a comparison with first generation products","volume":"5","author":"Pock","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"Suppl 6","key":"10.1016\/j.thromres.2010.11.030_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2516.2006.01373.x","article-title":"Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development","volume":"12","author":"Ettingshausen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2010.11.030_bb0115","series-title":"Immune tolerance and chioce of concentrates","first-page":"55","author":"Kreuz","year":"2002"},{"key":"10.1016\/j.thromres.2010.11.030_bb0120","series-title":"Blood and biotechnology","first-page":"169","year":"2009"},{"key":"10.1016\/j.thromres.2010.11.030_bb0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2516.2007.01558.x","article-title":"Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2010.11.030_bb0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.11.030_bb0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2516.2006.01200.x","article-title":"Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction","volume":"12","author":"Hodge","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2010.11.030_bb0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2516.2001.00530.x","article-title":"von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients","volume":"7","author":"Kallas","year":"2001","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2010.11.030_bb0145","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(08)70003-3","article-title":"The role of VWF for the success of immune tolerance induction","volume":"122","author":"Kreuz","year":"2008","journal-title":"Thromb Res"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810006651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810006651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T22:25:22Z","timestamp":1712096722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384810006651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0049384810006651"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2010.11.030","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}